The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease

被引：23
|
作者：
Verkleij, Chantal J. N. [1 ]
de Bruijn, Roderick E. [2 ]
Meesters, Eelco W. [2 ]
Gerdes, Victor E. A. [2 ,3 ]
Meijers, Joost C. M. [1 ,3 ]
Marx, Pauline F. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
来源：
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2011年 / 17卷 / 06期
关键词：
cardiovascular disease; coagulation; fibrinolysis; hemostasis; type 2 diabetes mellitus; PLASMINOGEN-ACTIVATOR INHIBITOR; VON-WILLEBRAND-FACTOR; 1ST-DEGREE RELATIVES; INSULIN; PLASMA; NIDDM; COMPLICATIONS; COAGULATION; FIBRINOGEN; RISK;
D O I：
10.1177/1076029610384112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes.
引用
收藏
页码：E57 / E63
页数：7
相关论文
共 50 条
  • [21] Predictors of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Tan, M. C.
    Wong, T. W.
    Chan, Y. M.
    Joseph, A.
    Hejar, A. R.
    Ng, O. C.
    [J]. INTERNATIONAL JOURNAL OF COLLABORATIVE RESEARCH ON INTERNAL MEDICINE & PUBLIC HEALTH, 2013, 5 (07) : 492 - 506
  • [22] Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease
    Vernstrom, Liv
    Funck, Kristian Lokke
    Grove, Erik Lerkevang
    Laugesen, Esben
    Baier, Jonathan Mathias
    Hvas, Anne-Mette
    Poulsen, Per Logstrup
    [J]. THROMBOSIS RESEARCH, 2018, 161 : 1 - 6
  • [23] Prognostic value of ECGs in patients with type-2 diabetes Mellitus without known cardiovascular disease
    de Santiago, Ana
    Garcia-Lledo, Alberto
    Ramos, Esther
    Santiago, Catalina
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (10): : 1035 - 1041
  • [24] CONTEMPORARY TREATMENT PATTERNS FOR NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS IN PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISEASE
    Koutroumpakis, Efstratios
    Hamden, Randa
    Deswal, Anita
    Tung, Poyee
    Nambi, Vijay
    Krause, Trudy
    Aguilar, David
    Aguilar, David
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 2041 - 2041
  • [25] Plasma metals and cardiovascular disease in patients with type 2 diabetes
    Long, Tengfei
    Wang, Ruixin
    Wang, Jing
    Wang, Fei
    Xu, Yali
    Wei, Yue
    Zhou, Lue
    Zhang, Xiaomin
    Yuan, Jing
    Yao, Ping
    Wei, Sheng
    Guo, Huan
    Yang, Handong
    Wu, Tangchun
    He, Meian
    [J]. ENVIRONMENT INTERNATIONAL, 2019, 129 : 497 - 506
  • [26] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Gaede, P
    Vedel, P
    Larsen, N
    Jensen, GVH
    Parving, H
    Pedersen, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05): : 383 - 393
  • [27] Glycemic variability and cardiovascular disease in patients with type 2 diabetes
    Martinez, Marcela
    Santamarina, Jimena
    Pavesi, Adrian
    Musso, Carla
    Umpierrez, Guillermo E.
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [28] Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
    Fujihara, Kazuya
    Sone, Hirohito
    [J]. ANNALS OF VASCULAR DISEASES, 2018, 11 (01) : 2 - 14
  • [29] Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without cardiovascular disease
    Magnusson, M
    Melander, O
    Israelsson, B
    Grubb, A
    Groop, L
    Jovinge, S
    [J]. DIABETES CARE, 2004, 27 (08) : 1929 - 1935
  • [30] Protein oxidation and cardiovascular disease in patients with type 2 diabetes
    Bryk, A. H.
    Konieczynska, M.
    Broniatowska, E.
    Undas, A.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 905 - 905
12345